ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

KDR

kinase insert domain receptor · also FLK1, VEGFR, VEGFR2, CD309 · CD molecules

15 programs in company-led studies act on KDR, from 14 companies: 9 in phase 3, 4 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (15 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
cabozantinibruleExelixisinhibitorphase 43610 runningMETChEMBL
lenvatinibruleEisaiinhibitorphase 4815 runningFLT1, FLT4NCIt
regorafenibruleBayerinhibitorphase 4404 runningABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEKChEMBL
nintedanibruleBoehringer Ingelheiminhibitorphase 4761 runningFGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, PDGFRA, PDGFRBChEMBL
zanzalintinibruleExelixisinhibitorphase 31715 runningAXL, METNCIt
apatinibruleJiangsu HengRui Medicineinhibitorphase 3478 running–ChEMBL
anlotinibruleSino Biopharmaceuticalinhibitorphase 3407 runningFLT4, KIT, PDGFRBChEMBL
AXL/FLT3/VEGFR2 Inhibitor KC1036ruleBeijing Konruns Pharmaceuticalinhibitorphase 376 runningAXL, FLT3NCIt
RamucirumabruleEli Lilly–phase 3585 running–NCIt
vorolanibruleBetta Pharmaceuticalsinhibitorphase 3245 running–the studies' text
AxitinibrulePfizerinhibitorphase 3454 runningFLT1, FLT4ChEMBL
chiauranibruleChipscreen Biosciencesinhibitorphase 3154 runningAURKB, FLT1, FLT4ChEMBL
Aurora B/VEGFR/FGFR Inhibitor AL8326ruleAdvenchen Laboratories Nanjinginhibitorphase 384 running–NCIt
cp-547632rulePanOpticainhibitorphase 261 running–ChEMBL
Anti-PD-1/Anti-VEGFR2 Bispecific Antibody OTP-01ruleOttimo Pharma–phase 211 runningPDCD1NCIt

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.